Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.

Read the release: bit.ly/3KsOU6M

#psychedelictherapeutics #adjustmentdisorder